GILD - Gilead Sciences, Inc
An antiviral drug specialist best known for HIV and hepatitis C treatments, now expanding into oncology and inflammation through acquisitions and internal R&D.
Finlify Score
49.4 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$124.30
-1.03%
52W Range
$104.46 - $157.29
Market Cap
$166.9B
-1.0%Compared to previous day
2026 Q1 Revenue
$7.0B
-12.2%Changes from last reporting quarter
2026 Q1 EPS
$1.61
Diluted shares
Analyst Rating
39 analysts in latest ratings feed
RSI
32.2
<40 oversold
2Y Range Position
65%
-21.0% from high / +98.3% from low
Beta
0.36
Relative to market benchmark
MACD
-0.54
MACD line -2.36 / signal line -1.83
Fundamental Trend
Growth 35.7Financial Health
Quality 87.6Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD49.4 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $7.0B-12.2% | $7.9B+2.0% | $7.8B+9.7% | $7.1B+6.2% |
| Gross Profit | - | - | - | - |
| Operating Income | $2.6B+30.3% | $2.0B-40.4% | $3.3B+34.5% | $2.5B+10.6% |
| Net Income | $2.0B-7.4% | $2.2B-28.5% | $3.1B+55.7% | $2.0B+49.0% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
The Finlify signal for Gilead Sciences, Inc. (GILD) is currently 'HOLD', with a Finlify Score of 51.7 out of 100, suggesting a neutral stance based on the comprehensive data available.
Technical
The asset's Relative Strength score of 34.4/100 appears relatively low, indicating some underperformance compared to its peers. Recent price action shows a 20-day return of -4.9% and a 60-day return of -11.1%, with the stock trading -19.4% below its 52-week high, which may suggest a period of price weakness. However, the Accumulation / Volume score of 64.9/100 indicates some underlying buying interest despite the recent price declines.
Fundamentals
GILD exhibits strong Financial Quality with a score of 87.6/100, suggesting robust financial health. However, the Fundamental Trend score of 35.7/100 appears weaker, potentially indicating some concerns regarding recent fundamental momentum. The asset trades at a P/E of 18.3x and offers a dividend yield of 2.61%, while its low Beta of 0.4 suggests lower sensitivity to overall market movements.
Macro Context
With a 10Y Treasury Yield at 4.5% and a 2Y Treasury Yield at 4.0%, the positive yield spread of 0.4% may suggest a less restrictive monetary outlook, which could generally support equity valuations. Inflation metrics like CPI YoY at 4.3% and Core PCE YoY at 3.3% are still elevated, potentially influencing the broader economic environment for a biotechnology company like GILD.
Key Risks
- Sustained weakness in the Fundamental Trend score of 35.7/100 may indicate underlying business challenges.
- Recent price underperformance, with a 60-day return of -11.1% and a Relative Strength score of 34.4/100, suggests a lack of positive momentum.
- The elevated inflation environment, with CPI YoY at 4.3%, could potentially impact operational costs or future pricing power for GILD.